CVS Health

CVS rose 0.78% to close at $107.72 today, gaining 34.46% year-to-date and approaching its 52-week high of $110.68. The primary catalyst driving the recent rally is the FTC settlement of CVS Caremark's PBM business practices, which could save consumers up to $13 billion and effectively resolves long-standing regulatory scrutiny. Strong earnings provide solid support: Q1 2026 EPS reached $2.30, up 63% year-over-year, while net profit surged 65% to $2.943 billion, though operating revenue grew more modestly at 6.15% to $99.852 billion, signaling meaningful improvements in cost management and operational efficiency. Analyst firms like Truist have recently raised price targets for health insurers, citing recovery prospects in profit margins. However, the current P/E ratio of 46.89 remains relatively elevated, and with the stock near all-time highs, further appreciation may face headwinds from elevated expectations.

CVS Health pulled back modestly to $106.89 today, declining 0.49%, mainly due to profit-taking pressures following its recent sharp rally. The retreat follows yesterday's 52-week high of $110.68—despite gaining 33.4% year-to-date, the stock has now retreated 3.42% from its peak. The primary catalyst for the recent rally was CVS Caremark's settlement with the FTC, which ends the federal investigation into its pharmacy benefit management business and is expected to save consumers up to $13 billion, successfully driving the record high yesterday. On the operations front, the Aetna insurance division remains solid, bolstered by a recent multi-year contract renewal with Memorial Healthcare System. Notably, unusually large options volume has emerged in the market recently, potentially signaling trader divergence on near-term direction. From a fundamental perspective, Q1 2026 EPS of $2.30 surged 63% year-over-year with steady revenue growth of 6.15% to $99.85 billion, though the current P/E valuation of 46.5x remains elevated and may constrain further upside momentum.

CVS Health pulled back 2.3% to $108.08 today, driven primarily by profit-taking following recent positive catalysts — the company's FTC settlement on its Caremark unit (saving consumers up to $13 billion) and dividend increase to $0.67 per share pushed the stock to a 52-week high of $110.68, yet elevated valuations (P/E of 47x) and year-to-date gains of 34.88% triggered a correction. Pre-market trading saw the stock briefly surge to $111 (7:20 AM ET), but the regular session opened weaker at $109.68 and declined to $107.91 (3:55 PM ET), recovering to $108.52 in post-market hours. Technically, the stock trades well above both its 20-day moving average of $105.18 and 60-day average of $96.89, remaining just 2.35% below the 52-week peak.

CVS surged 2.7% today, hitting a 52-week high of $110.62 during regular hours and further rallying to $111.00 in post-market trading, primarily driven by the FTC settlement agreement with CVS Caremark regarding PBM practices, expected to save consumers up to $13 billion. Fundamentally, the company reported Q1 EPS of $2.30 and operating revenue of $99.85 billion, growing 63.1% and 6.15% year-over-year respectively, with net income rising 65.4% and operating income up 25.1%. Technically, CVS shares are up 38% year-to-date and trade well above their 20-day and 60-day moving averages. While the current PE ratio of 48.13 appears elevated, institutional support remains strong, with Dimensional Fund increasing its position and Truist upgrading industry target prices.

CVS closed relatively flat at 107.61 after a pre-market surge to 109.82 that failed to sustain, reflecting profit-taking pressure following a robust year-to-date gain of 34.29% approaching the 52-week high of 108.97. Recent catalysts include an FTC settlement regarding CVS's PBM practices that could save consumers up to 13 billion dollars—hailed as an industry-leading approach to transparency—and the opening of its first pharmacy-centric store in Houston as part of a retail strategy repositioning. Q1 2026 earnings delivered strength across the board, with operating revenue of 99.85 billion dollars up 6.15% year-over-year, net profit of 2.94 billion up 65.43% YoY, and EPS growth of 63% compared to the year-ago quarter. The stock trades well above its 60-day moving average of 95.86, with a market cap of 137.3 billion dollars. However, an elevated PE valuation of 46.83 may continue to cap near-term upside as high-level consolidation persists.